544 related articles for article (PubMed ID: 15277497)
1. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
Kim H; Robinson MR; Lizak MJ; Tansey G; Lutz RJ; Yuan P; Wang NS; Csaky KG
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2722-31. PubMed ID: 15277497
[TBL] [Abstract][Full Text] [Related]
2. Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging.
Kim SH; Galbán CJ; Lutz RJ; Dedrick RL; Csaky KG; Lizak MJ; Wang NS; Tansey G; Robinson MR
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):808-14. PubMed ID: 17251481
[TBL] [Abstract][Full Text] [Related]
3. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants.
Okabe K; Kimura H; Okabe J; Ogura Y
Retina; 2007; 27(6):770-7. PubMed ID: 17621189
[TBL] [Abstract][Full Text] [Related]
4. GD-DTPA enhanced MRI of ocular transport in a rat model of chronic glaucoma.
Chan KC; Fu QL; Guo H; So KF; Wu EX
Exp Eye Res; 2008 Oct; 87(4):334-41. PubMed ID: 18639546
[TBL] [Abstract][Full Text] [Related]
5. Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging.
Kim H; Lizak MJ; Tansey G; Csaky KG; Robinson MR; Yuan P; Wang NS; Lutz RJ
Ann Biomed Eng; 2005 Feb; 33(2):150-64. PubMed ID: 15771269
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
Robinson MR; Baffi J; Yuan P; Sung C; Byrnes G; Cox TA; Csaky KG
Exp Eye Res; 2002 Feb; 74(2):309-17. PubMed ID: 11950241
[TBL] [Abstract][Full Text] [Related]
7. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents.
Kimura J; Ishiguchi T; Matsuda J; Ohno R; Nakamura A; Kamei S; Ohno K; Kawamura T; Murata K
Radiat Med; 2005 Aug; 23(5):322-6. PubMed ID: 16342903
[TBL] [Abstract][Full Text] [Related]
8. Delivery from episcleral exoplants.
Pontes de Carvalho RA; Krausse ML; Murphree AL; Schmitt EE; Campochiaro PA; Maumenee IH
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4532-9. PubMed ID: 17003449
[TBL] [Abstract][Full Text] [Related]
9. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
Alikacem N; Yoshizawa T; Nelson KD; Wilson CA
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677
[TBL] [Abstract][Full Text] [Related]
10. Quantitative magnetic resonance imaging in assessment of the blood-retinal barrier.
Plehwe WE; McRobbie DW; Lerski RA; Kohner EM
Invest Ophthalmol Vis Sci; 1988 May; 29(5):663-70. PubMed ID: 3366561
[TBL] [Abstract][Full Text] [Related]
11. Accurate and precise measurement of blood-retinal barrier breakdown using dynamic Gd-DTPA MRI.
Berkowitz BA; Tofts PS; Sen HA; Ando N; de Juan E
Invest Ophthalmol Vis Sci; 1992 Dec; 33(13):3500-6. PubMed ID: 1464496
[TBL] [Abstract][Full Text] [Related]
12. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG
Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease.
Kim H; Csaky KG; Gilger BC; Dunn JP; Lee SS; Tremblay M; de Monasterio F; Tansey G; Yuan P; Bungay PM; Lutz RJ; Robinson MR
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):655-62. PubMed ID: 15671296
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant.
Kato A; Kimura H; Okabe K; Okabe J; Kunou N; Ogura Y
Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):238-44. PubMed ID: 14691179
[TBL] [Abstract][Full Text] [Related]
15. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
[TBL] [Abstract][Full Text] [Related]
16. Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging.
Kim SH; Csaky KG; Wang NS; Lutz RJ
Pharm Res; 2008 Mar; 25(3):512-20. PubMed ID: 17674155
[TBL] [Abstract][Full Text] [Related]
17. Episcleral implants for topotecan delivery to the posterior segment of the eye.
Carcaboso AM; Chiappetta DA; Opezzo JA; Höcht C; Fandiño AC; Croxatto JO; Rubio MC; Sosnik A; Abramson DH; Bramuglia GF; Chantada GL
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2126-34. PubMed ID: 19834044
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
19. Development of a conjugated gadolinium and cisplatin-gelatin possessing properties as an intravascular contrast agent for MR imaging.
Sonoda A; Nitta N; Ohta S; Seko A; Jo J; Morikawa S; Tabata Y; Takahashi M; Murata K
Eur J Radiol; 2009 Sep; 71(3):570-5. PubMed ID: 18502598
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging.
Port RE; Schuster C; Port CR; Bachert P
Cancer Chemother Pharmacol; 2006 Nov; 58(5):607-17. PubMed ID: 16506037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
